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Abstract 
 
The immunomodulatory actions of parasitic helminth excretory-secretory (ES) products that 
serendipitously protect against development of chronic inflammatory disorders are well 
established: however, knowledge of the interaction between ES products and the host 
musculoskeletal system in such diseases is limited. In this study, we have focused on ES-62, a 
glycoprotein secreted by the rodent filarial nematode Acanthocheilonema viteae that is 
immunomodulatory by virtue of covalently attached phosphorylcholine (PC) moieties, and 
also two synthetic drug-like PC-based small molecule analogues (SMAs) that mimic ES-62Õs 
immunomodulatory activity. We have previously shown that each of these molecules prevents 
development of pathology in collagen-induced arthritis (CIA), a model of the musculoskeletal 
disease, rheumatoid arthritis (RA) and reflecting this, we now report that ES-62 and its SMAs, 
modify bone remodeling by altering bone marrow progenitors and thus impacting on 
osteoclastogenesis. Consistent with this, we find that these molecules inhibit functional 
osteoclast differentiation in vitro. Furthermore, this appears to be achieved by induction of 
anti-oxidant response gene expression, thereby resulting in reduction of the reactive oxygen 
species production that is necessary for the increased osteoclastogenesis witnessed in 
musculoskeletal diseases like RA.  
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1. Introduction  
 
The musculoskeletal disease rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory 
condition that results in the debilitating loss of articular bone in affected joints (1). 
Inflammation in such joints is orchestrated by the hyper-proliferative responses of synovial 
fibroblasts and infiltration of activated leukocytes, resulting in bone erosion that can be 
present prior to manifestation of clinical disease (2). Cells associated with bone remodeling 
such as osteoclasts (OCs), and also immune system cells including T and B lymphocytes, rely 
on cytokines like Receptor Activator of NF-κB Ligand (RANKL), osteoprotegerin (OPG) and 
pro-inflammatory mediators to control cell maturation and pathogenic responses. These events 
occur in the lymph node and bone marrow (BM) and additionally drive OC differentiation at 
bone remodelling sites in arthritic joints (3). Thus, in patients with RA, synovial fibroblasts 
and T cells produce increased levels of RANKL and interleukin (IL)-17 compared to healthy 
controls, leading to the dysregulated differentiation of OCs at the articular surface, and 
consequently resulting in erosion and deformation of bone (4,5).  
 
This aberrant osteoclastogenesis contrasts with the tightly regulated interactions between OCs 
and their bone forming partners, osteoblasts (OBs), that continuously act to maintain 
homeostatic renewal of bone (6). In this case, OCs differentiate from OC precursors (OCPs) in 
the monocyte lineage and are recruited to the bone where OBs produce Macrophage-Colony 
Stimulating Factor (M-CSF) and RANKL to stimulate terminal OC differentiation (3). The 
interaction between RANKL and its receptor RANK activates the transcription factor NFATc1 
which controls the production of DC-STAMP and Cathepsin K that are essential for the fusion 
and function of mature bone-eroding cells (7Ð10). In addition, the process of 
osteoclastogenesis is reliant on the production of reactive oxygen species (ROS) as both M-
CSF and RANKL signaling induce ROS to enhance OC differentiation and moreover, 
treatment with N-acetyl-l-cysteine (NAC), a scavenger of ROS, inhibits the differentiation of 
OCs preventing RANKL-induced ROS (11,12). Importantly, scavenging ROS with the aid of 
NAC in synovial fibroblasts isolated from RA patients results in their decreased RANKL 
production and inhibited Th17 differentiation (13). 
 
Although the immunomodulatory properties of parasitic helminths and their excretory-
secretory (ES) products in modulating inflammatory diseases including RA are well 
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documented, the effects of the helminths or their ES products on bone during such conditions 
remains poorly studied. Amongst the most widely characterized helminth ES products is the 
phosphorylcholine (PC)-containing glycoprotein ES-62, produced by Acanthocheilonema 
viteae (14,15). It is well-established that ES-62, via its PC moieties, prevents the development 
and progression of arthritic disease, with histopathological analysis demonstrating that it not 
only suppresses inflammatory cell infiltration of the joints but also reduces cartilage and bone 
damage, in the murine model of RA, collagen-induced arthritis (CIA) (14,16,17). Specifically, 
ES-62 promotes IL-22-mediated tissue repair responses in the joint while disrupting Th17 and 
IL-17-producing γδ T cell inflammatory networks to facilitate the resolution of disease (16,17). 
Likewise, drug-like small molecule analogues (SMAs) based on the active PC moiety of ES-
62 mimic both the anti-inflammatory and bone protective effects of ES-62 and thereby prevent 
the development and progression of joint damage associated with arthritis in CIA (18Ð20). 
 
We therefore aimed to investigate whether these helminth-derived agents could also impact on 
pathogenic osteoclastogenesis to resolve inflammation and joint damage in the CIA model. In 
doing so, we have established that treatment with ES-62 can alter BM monocyte populations 
in vivo and reduce functional OC differentiation in vitro. We also demonstrate that the drug-
like SMAs based on this helminth product, mimic ES-62Õs ability to modulate OC 
differentiation in vitro by orchestrating an anti-oxidant response that suppresses ROS 
production. 
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2. Methods 
 
2.1. Animals 
 
Male 6-8-week-old C57BL/6 mice were bred and maintained under specified pathogen-free 
and standard ad libitum conditions at the University of StrathclydeÕs Biological Procedures 
Unit. Male 6-8 week-old DBA/1 mice (Envigo; Bicester, UK) were housed and maintained in 
the Central Research Facility of the University of Glasgow. All experiments were approved by, 
and conducted in accordance with, the Animal Welfare and Ethical Review Boards of the 
Universities of Strathclyde and Glasgow and UK Home Office Regulations and Licenses PIL 
I518666F7, PPL 60/4314, PPL P8C60C865, PIL 1675F0C46 and PIL ICEBDB864. 
 
2.2. Collagen-Induced Arthritis (CIA) 
 
CIA was induced in male DBA/1 mice (8-10 week-old; ~ 20g) following intradermal 
immunization with 100 µg of bovine Collagen Type II (CII) emulsified with complete FreudÕs 
adjuvant (MD Biosciences) on day 0 with a further injection of 200 µg CII in PBS given 
intraperitoneally on day 21 as described previously (14). Animals were treated via the 
subcutaneous route with either PBS or 2 µg/injection of ES-62 (~ 0.1mg/kg) on days -2, 0 and 
21 and joint inflammation was scored as previously described (14). Disease articular scores 
were assessed daily as 0 (normal), 1 (erythema), 2 (erythema plus swelling), 3 (extension of 
swelling) or 4 (loss of function), with the overall score being the sum of those from all 4 
limbs: animals were culled when at least one of the PBS control group had reached a score of 
10 or clinical symptoms developed in all 4 limbs. Joint damage was also routinely assessed by 
histopathology. Typically, disease incidences ≥ 80 %, where incidence is defined as the 
percentage of animals achieving an articular score ≥ 1, are achieved by about day 30, with 
articular scores generally plateauing around this time (14,16Ð21). Purified endotoxin-free ES-
62 and SMAs 11a, 12b and 19o were prepared as previously described (14,18). 
 
2.3. Histology 
 
Paws from CIA-mice were fixed in 4% paraformaldehyde prior to decalcification and paraffin 
wax embedding for H&E staining (7 ȣm sections) following a standard protocol. For 
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Cathepsin K detection by immunofluorescence, sections were cleared in histoclear and 
rehydrated before antigen retrieval in Citrate Buffer for 20 minutes at 95
o
C.  Sections were 
blocked in 10% FBS in PBS for 30 minutes at room temperature (RT), endogenous 
avidin/biotin was quenched (Vector Laboratories, UK) and sections incubated overnight at 
4
o
C with rabbit anti-mouse Cathepsin K (Abcam, UK). Sections were then incubated for 60 
minutes at RT with biotinylated goat anti-rabbit IgG (Vector Laboratories, UK) and followed 
with Streptavidin-conjugated Alexa Fluor 647 (Vector Laboratories, UK) for 30 minutes at RT. 
DAPI (1 µg /ml) was used as a nuclear stain (Sigma-Aldrich, UK). Sections were washed in 
PBS with 0.05% (v/v) Tween-20 between each incubation.  Following staining, sections were 
dehydrated through ethanol, mounted and Cathepsin K
+ 
multinucleated cells on the bone 
surface were enumerated using an EVOS FL Auto Cell Imaging System.  
 
2.4. Flow Cytometry 
 
BM cells were suspended in FACS buffer (2.5% BSA; 0.5mM EDTA, in PBS) following red 
cell-lysis with 0.8% NH4Cl buffer. Phenotypic surface markers were labelled using PE-
conjugated anti-CD3/B220/Ter119, FITC anti-CD11b, PerCP-Cy5.5 anti-Ly6C, APC anti-
Ly6G or CD11b and Biotin anti-CD115 antibodies and APC Cy7 conjugated Streptavidin 
(Biolegend). Cells were stained with 7AAD (BD Bioscience, UK) to assess cell death. For 
hematopoietic stem cell (HSC) analysis, PE-conjugated lineage cocktail and PE-conjugated 
isotype antibodies were used alongside FITC anti-Sca-1 and APC anti-CD117 antibodies. 
Data were acquired using a FACS Canto flow cytometer and analysed using FlowJo Software 
(Tree Star In, OR USA, version 8.8.7) and populations were gated using isotype and 
fluorescence minus one (FMO) controls. 
 
2.5. In vitro OC differentiation  
 
OCs were differentiated from nave C57BL/6 or DBA/1 mice that were either nave control 
animals or DBA/1 mice that had undergone CIA and received either PBS or ES-62 treatments, 
in vivo. BM was flushed from the tibias and femurs of these mice using a sterile 23-gauge 
needle and syringe in PBS and aspirated to create a single cell suspension. This single cell 
suspension was then passed through a 20 µm cell strainer prior to centrifugation at 400xg and 
re-suspension in PBS. Following cell counting, single cells were washed and re-suspended at 
1x10
6
/ml in ÒcompleteÓ αMEM medium (containing 50 U/ml penicillin, 50 µg/ml 
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streptomycin and 10% FCS) and 9 ml of cell suspension were incubated overnight with 30 
ng/ml M-CSF (Peprotech, London, UK). Following overnight incubation at 37
o
C in 5% CO2, 
non-adherent BM cells were removed, counted, and re-suspended in fresh complete αMEM 
medium supplemented with 30 ng/ml M-CSF and 50 ng/ml RANKL at 0.5x10
6
 cells/ml. 
These non-adherent BM cells (200 µl) were then seeded in 96 well tissue-culture plates to 
initiate OC differentiation. Preliminary experiments established that whilst treatment of cells 
with phosphorylcholine conjugated to Bovine Serum Albumin (PC-BSA) from day 1-4 did not 
inhibit the numbers of OCs generated, exposure to PC-BSA at day 4 resulted in inhibition of 
the OC fusion underpinning generation of large multinucleated OCs (data not shown). Thus 
medium was refreshed on day 4 and treated with vehicle, ES-62, Bovine Serum Albumin 
(BSA - Sigma-Aldrich, UK), phosphorylcholine conjugated to BSA (PC-BSA) (22), 
phosphorylcholine chloride (PC - Sigma, UK) or SMAs 11a, 12b or 19o, at the indicated 
concentrations, for 24 hours prior to assessment of functional maturation. Cells were assessed 
for OC differentiation by TRAP staining (Leukocyte Acid Phosphatase Kit, Sigma, UK) on 
days 4, 5 and 6 as indicated and cells that stained positive for TRAP with ≥ 3 nuclei were 
counted as OCs. The average size of individual OCs per field of view (FOV) was calculated 
using Image J software. Images were obtained on an EVOS FL Auto Cell Imaging System or a 
Leica DM IL LED at 4x magnification with scale bars set at 1000 µm.  
 
2.6. In vitro bone resorption assay 
 
Dentine discs (Immunodiagnostics Systems Ltd., UK) were used to measure the functional 
capacity of differentiated OCs. Briefly, non-adherent BM was cultured on dentine discs for 14 
days with medium refreshed every 4
th
 day. Vehicle controls and treatments were commenced 
on day 4 and added with every medium replacement. OCs were lysed on dentine discs by 
incubation with distilled dH20 prior to visualization of resorption pits using black ink. The 
area of resorption was measured as a percentage of the total area using Image J software.  
Images were obtained on an EVOS FL Auto Cell Imaging System or a Leica DM IL LED at 
10x magnification with scale bars set at 400 µm. 
 
2.7. qRT-PCR 
 
BM cells (10
6
), or
 
OCs that were pre-treated with SMAs (5 µg/ml) for 24 hours, were lysed in 
RNeasy Lysis Buffer prior to mRNA extraction using RNeasy Plus Mini kit (Qiagen, 
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Germany) according to manufacturerÕs instructions. Additionally, cleaned and flushed femurs 
and tibias were then flushed with QIAzol to obtain RNA from bone lining cells as previously 
described (23). cDNA was generated using High Capacity cDNA Reverse Transcriptase kit 
(Applied Biosystems, Life Technology) before use in PCR amplifications using the StepOne 
Plusª real-time PCR system (Applied Biosystems). KiCqStart¨ qPCR Ready Mix (Sigma-
Aldrich) was used in conjunction with the following primer pairs: osteopontin (spp1; Forward 
Ð GGATGAATCTGACGAATCTC, Reverse - GCATCAGGATACTGTTCATC), RANK 
(tnfrsf11a; Forward Ð GAAATAAGGAGTCCTCAGGG, Reverse - 
TAGAATCTCTGACTTCTGCC), RANKL (tnfsf11; forward Ð 
TCTGTTCCTGTACTTTCGAG, reverse - TTCATGGAGTCTCAGGATTC), OPG 
(tnfrsf11b; forward Ð GAAGATCATCCAAGACATTGAC, reverse - 
TCCTCCATAAACTGAGTAGC), DC-STAMP (dcstamp; forward Ð 
TCTGCTGTATCGGCTCATCTC, reverse - ACTCCTTGGGTTCCTTGCTT), Cathepsin K 
(ctsk; forward Ð CAGAGGGTACAGAGAGATTC, reverse - 
TCATCATAGTACACACCTCTG), MMP9 (mmp9; forward Ð 
CTTCCAGTACCAAGACAAAG, reverse - ACCTTGTTCACCTCATTTTG), NFATc1 
(nfatc1; forward Ð CCAAGTCAGTTTCTATGTCTG, reverse - 
ATAATTGGAACATTGGCAGG), β3 (itgb3; forward Ð TATAGTGAGCTCATTCCTGG, 
reverse - ATTTTCCCGTAAGCATCAAC) and β-actin (actb; forward Ð 
GATGTATGAAGGCTTTGGTC, reverse - TGTGCACTTTTATTGGTCTC). TaqManª 
master mix (Applied Biosystems) was used to analyze the following set of genes; HMOX-1 
(Hmox1- Mm00516005_m1), GCLM (gclm - Mm00514994_m1), GCLC (gclc - 
Mm00802655_m1) and GAPDH (gapdh - Mm99999915_g1). Data were normalised to the 
reference genes GAPDH or β-actin to obtain the ΔCT values that were used to calculate the 
fold-change from the ΔΔCT following normalisation to the biological control group. 
 
2.8. Reactive Oxygen Species (ROS) Assay 
 
The presence of ROS was measured on day 5 of the OC differentiation assay, following 24 
hour pre-treatment with SMAs, using 2Õ,7Õ-dichlorofluorescein diacetate (DCF-DA, Sigma, 
UK) . Briefly, to measure ROS, cells were washed in pre-warmed PBS twice prior to 
incubation with 100 µl of 50 µM DCF-DA for 30 minutes at 37
o
C. Following washing in PBS, 
fluorescence was detected at 492 nm excitation and 529 nm emission wavelengths. Unstained 
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cells were used to control for background fluorescence and biological replicates were 
normalised to controls. 
 
2.9. Statistics 
 
All data were analysed using GraphPad Prism 6 software. For parametric data, StudentÕs t-test 
or One-Way ANOVA with BonferroniÕs or Fishers LSD post-tests were employed. Non-
parametric data were analysed using Kruskal-Wallis test and DunnÕs post-test or Mann-
Whitney U test. Indicators or significance include * = p < 0.05, ** = p < 0.01 and *** = p < 
0.001. 
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3. Results 
 
3.1. ES-62 normalizes the BM OC progenitor populations in arthritic animals 
 
In line with our previously published observations (14), DBA/1 mice treated with ES-62 were 
protected from developing arthritis in the CIA model both in terms of articular score (Figure 
1A and B) and disease incidence (Figure 1A: PBS, 87.5%; ES-62, 0%). This impact of ES-62 
on disease pathology was confirmed by H&E staining of joint sections (Figure 1C), which 
showed that exposure to the parasite product reduced inflammatory cell infiltration and 
cartilage and bone destruction. Additionally, upon analysis of representative animals from 
each group, the levels of Cathepsin K
+
 OCs found in such sections were decreased in the paws 
of ES-62-treated animals compared to those of PBS-treated CIA animals, returning to the 
levels found in joints from Nave healthy DBA/1 mice (Figure 1D and E). To understand the 
effect of inflammatory arthritis on BM progenitors we identified hematopoietic stem cells 
(HSCs) within the BM of animals undergoing CIA. Analysis of Sca-1
+
CD117
+ 
cells within the 
Lineage
neg
 population showed that PBS-treated CIA animals had an increased proportion of 
HSCs in the BM compared to both Nave and ES-62-treated CIA animals (Figure 1F). The 
BM HSC population is supported and maintained by stromal and OB production of 
osteopontin (OPN) but analysis of OPN mRNA in the bone lining cells (23) of the femurs and 
tibias showed that OPN mRNA levels were not significantly different in PBS-treated CIA 
mice relative to Nave and ES-62-treated CIA animals (Figure 1G). As ES-62 is able to return 
HSC levels to those found in healthy animals and show evidence of reducing Cathepsin K
+
 
OC numbers in the joints of arthritic mice, we next aimed to determine specifically whether 
CIA would affect defined OC progenitor populations in the BM. Due to their differentiation 
from the myeloid lineage, we focused on phenotypic analysis of both monocyte (CD3
-
B220
-
Ter119
-
Ly6G
-
Ly6C
high
) and OCP (CD3
-
B220
-
Ter119
-
Ly6G
-
Ly6C
high 
CD11b
low
) populations 
(Figure 1H), as OCPs constitute a small population of cells within the umbrella of monocyte 
heterogeneity, as defined by Charles et al (24).  Our analysis showed that treatment with ES-
62 reduced the absolute percentage (%) of monocytes within the BM of mice undergoing CIA 
(Figure 1I). Moreover, CIA (PBS) increased the % of OCPs in the BM compared to Nave 
animals (Figure 1J): although treatment with ES-62 was unable to significantly alter the level 
of BM OCP populations observed from that in PBS-treated CIA animals, the % of OCPs 
present in ES-62 treated CIA animals was not significantly different from that of Nave 
animals, suggesting that ES-62 was having some effect in reducing the % of these progenitor 
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cells in BM of CIA animals. In addition, ES-62 treatment was able to decrease the expression 
of CD115 (the M-CSF receptor) on the surface of both monocytes (Figure 1K) and OCPs 
(Figure 1L) compared to PBS-treated CIA animals, an effect that would decrease their ability 
to differentiate into OCs during inflammation.  
 
3.2. ES-62 alters the functional differentiation of osteoclasts and the bone remodelling 
axis in arthritic animals  
 
Previously, exposure to ES-62 was found to alter differentiation of macrophages from BM 
progenitors (25) and therefore given its effects on OCPs, we next aimed to investigate whether 
OC differentiation from ES-62-treated CIA-mouse BM was altered compared to that from 
PBS-treated CIA animals. OCs are short-lived cells with their apoptosis playing roles in 
regulating osteoclastogenesis (26,27): thus, due to the dynamic nature of their differentiation 
and cell death (26), a time course of OC differentiation was performed to observe the effects 
of in vivo exposure to ES-62 on the kinetics and extent of differentiation of OCs derived from 
BM of mice undergoing CIA. As shown in Figure 2A and B, by day 4 comparable levels of 
osteoclastogenesis in terms of OC number and size were observed amongst treatment groups: 
however, by day 5, there was a significant increase in cell fusion associated with CIA resulting 
in a decrease in cell number but an increase in cell size in the PBS-treated CIA animals 
compared to Nave and ES-62 treated animals. By the sixth day of culture the majority of large 
multinucleated cells have begun to apoptose (Fig. 2C) with similar levels of live cells 
remaining in the PBS- and ES-62-treatment groups. Representative images of OC 
differentiation are provided with cell death indicated by red arrows (Figure 2C). To assess the 
functional capacity of the BM progenitors from Nave and PBS- and ES-62-treated CIA 
animals the BM was cultured for fourteen days on dentine slices, revealing that ES-62-CIA 
BM had a reduced ability to resorb bone compared to PBS-CIA BM (Figure 2 D and E). 
 
In order to further understand how the inflammatory milieu in arthritic animals influences the 
OC progenitor populations and the differentiation potential of OCs, the RANK/OPG/RANKL 
bone remodelling axis was analysed. Whole BM lysates, collected at cull, were used to 
analyse the mRNA transcripts of RANK (tnfrsf11a), OPG (tnfrsf11b) and RANKL (tnfsf11) to 
identify potential changes that occur during disease and that may be (differentially) modified 
following treatment with ES-62. As shown in Figure 2F, the mRNA level for RANK was not 
significantly changed in PBS-treated CIA animals compared to Nave controls. However, 
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treatment with ES-62 resulted in a decrease in RANK transcript. Similarly, OPG mRNA levels 
were unchanged in PBS-treated animals compared to Nave animals, however, ES-62 
treatment increased OPG mRNA in the BM of animals, although this did not reach statistical 
significance (Figure 2G). No changes were observed in RANKL mRNA levels between Nave 
and PBS- treated animals, while ES-62 treatment strikingly decreased RANKL mRNA 
compared to PBS-treated CIA animals (Figure 2H).  
 
Overall, the data in Figures 1 and 2 indicate that arthritic disease in DBA/1 animals 
undergoing CIA alters both the levels of OC progenitor populations and their potential to form 
large multinucleated OCs, while the helminth product ES-62 acts to restore the level of OCPs 
to that resembling BM OCPs from Nave DBA/1 animals and inhibit their functional 
maturation. Whilst the RANK/RANKL/OPG bone-remodeling axis is not substantially altered 
during CIA, the changes in RANK/RANKL/OPG mRNA induced by ES-62 treatment may 
account for the modulation of progenitor populations and their subsequent capacity to undergo 
osteoclastogenesis and indicate that ES-62 does not simply prevent the rewiring of progenitors 
occurring in the Nave to CIA transition.  
 
3.3. ES-62 modulates differentiation of osteoclast functional responses in vitro 
 
To directly address the mechanisms involved in ES-62-mediated modulation of OC responses, 
BM was cultured with M-CSF and RANKL for five days and Nave BM from both DBA/1 
and C57BL/6 mouse strains was employed, the latter to allow us to examine the potential for 
differences in OC differentiation and functional maturation between arthritis-prone and more 
resistant strains, respectively (28). Addition of ES-62 at day 4 did not inhibit OC 
differentiation in C57BL/6 animals but significantly inhibited OC fusion to generate large, 
multinucleated cells in a dose-dependent manner, with maximum inhibition at the highest 
concentration tested, 50 µg/ml (data not shown and Figure 3A, B and E). Whilst addition of 
ES-62 to DBA/1 cultures likewise significantly decreased the size of the resulting TRAP
+
 OCs, 
it also reduced the numbers of OCs differentiated from the BM of naive DBA/1 mice (Figure 
3C-E).  
 
PC-chloride (PC) and PC-conjugated to BSA (PC-BSA) were also tested in OC differentiation 
assays to determine whether the immunomodulatory PC-component of ES-62 was responsible 
for this novel effect on OCs. In the arthritis-resistant C57BL/6 animals, PC-BSA, but not PC, 
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significantly increased the number of OCs in culture, yet PC-BSA and PC treatment both 
generated OCs that were smaller in size than those in the M-CSF and RANKL controls 
(Figure 3A and B). In DBA/1 animals, neither PC-BSA not PC had an effect on the number of 
OCs generated but like ES-62, both significantly reduced the fusion of OCs resulting in 
smaller TRAP
+
 OCs (Figure 3C-E). BSA was used as a control for PC-BSA treatment and was 
shown to have no effect on the differentiation and functional maturation of OCs in either 
C57BL/6 or DBA/1 cultures (Figure 3A-E). Representative images are provided to 
demonstrate the inhibition in OC fusion observed in both C57BL/6 and DBA/1 BM cultures 
(Figure 3E).  
 
The bone resorption assay was then utilised to understand how ES-62 and the PC-containing 
molecules were affecting the functional capacity of the OCs undergoing reduced cell fusion 
during in vitro osteoclastogenesis. This showed that ES-62 (albeit not significantly relative to 
the M+R control) and PC-BSA reduced the levels of bone resorption induced compared to 
those in M-CSF plus RANKL controls (± BSA, Figure F and G). These effects on 
osteoclastogenesis were not due to reduced cell viability as 7AAD staining showed that 
treatment with ES-62, PC-BSA, PC or BSA all further reduced the very low levels of dead (% 
of 7AAD
+
CD11b
+
) cells resulting in culture when compared to those with M-CSF plus 
RANKL alone (M+R; Figure H).  Collectively, these data indicate that the immunomodulatory 
PC component of ES-62 is likely to be responsible for its ability to inhibit fusion and 
functional maturation of OCs. Moreover, the data suggest that exposure to ES-62/PC in vitro 
prevents the functional maturation of OCs derived from BM OCPs from both healthy 
C57BL/6 and DBA/1 mice, predominantly by recapitulating the reduced OC fusion found 
during ex vivo osteoclastogenesis of BM from CIA mice exposed to ES-62 in vivo (Figure 2).  
 
3.4. ES-62Õs small molecule analogues 11a and 12b inhibit osteoclast differentiation 
and functional maturation  
 
The PC moiety of ES-62 has been used as the structural starting-point to generate a library of 
drug-like synthetic small molecule analogues (SMAs) that mimic the immunomodulatory 
capabilities of ES-62: two of these, SMAs 11a and 12b recapitulate the anti-inflammatory and 
bone protective effects of ES-62 and are successful in preventing development and 
progression of joint damage in CIA (18Ð20). Thus, we investigated the effect of these 
compounds on in vitro OC differentiation, with addition of SMAs 11a or 12b (at 5 µg/ml) on 
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day 4. SMA 19o was used as a negative control for SMAs 11a and 12b, as in previous studies 
this SMA failed to mimic the protective immunomodulatory capabilities of ES-62, either in 
vivo or in vitro (18,29). In C57BL/6 and DBA/1 cultures, SMAs 11a and 12b significantly 
reduced both the number and the size of differentiated OCs, compared to M-CSF+RANKL 
exposure alone (M+R) whilst, by comparison, SMA 19o exhibited little or no effect (Figure 
4A-D). Representative images of SMA-treated C57BL/6 OCs are provided to highlight the 
reduction in the size of OCs compared to those produced following culture with M-
CSF+RANKL alone (M+R; Figure 4E). Furthermore, assessment of the ability of the SMAs to 
modulate OC function in the bone resorption assay showed that whilst SMA19o, if anything, 
tended to promote bone resorption, SMA11a and, to a lesser extent, 12b (albeit only 
significantly with respect to the SMA19o control) inhibited bone resorption (Figure 4F and G).  
 
Due to their therapeutic potential, we wished to ensure that the effects of the SMAs did not 
reflect induction of cell death: importantly analysis of cell viability showed that the % of 
7AAD
+
CD11b
+
 cells in SMA-treated cultures is not increased relative to M+R treatment alone 
(Figure 4H). Therefore, the effects of SMAs on OC differentiation and functional maturation 
are not due to cell death, findings consistent not only with our previous reports on SMA-
treated macrophages (18,19) but also with the effects of ES-62, PC-BSA and PC observed in 
Figure 3H. 
 
 
3.5. SMAs 11a and 12b alter mRNA transcription in osteoclasts and induce an anti-
oxidant response 
 
To identify the mechanisms underlying the observed SMA-mediated effects, the inhibition of 
OC differentiation by SMA 11a or 12b was further explored by examination of expression of 
key regulators of OC differentiation and function on cells that had been in culture for 5 days 
(Figure 5A-E). Interestingly, despite inhibiting differentiation and resorption, SMA 11a failed 
to have any effect on mRNA levels of the OC-specific genes investigated (Figure 5A-E), 
suggesting that this SMA utilises another mechanism to inhibit functional differentiation of 
OCs. By contrast, SMA 12b was able to decrease the mRNA levels of a number of essential 
OC genes (Figure 5A-E). For example, the master regulator of osteoclastogenesis, NFATc1, 
was decreased following SMA 12b exposure (Figure 5A) and indeed, inhibition of this 
transcription factor by SMA 12b is likely to account for its effects on expression of the key 
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markers of OC differentiation, MMP9, Cathepsin K, DC-STAMP and §3 (Figure 5B-
E)(10,30) and perhaps explains its dramatic effects on the differentiation and fusion of TRAP
+
 
OCs. As expected, SMA 19o generally had little or no effect in this analysis.  
 
Previously, SMA 12b was shown to require NRF2 for its inhibition of pro-inflammatory 
cytokine release by macrophages (19), particularly that of IL-1β which also plays a key role in 
promoting osteoclastogenesis and bone resorption (31). As SMA 12b-mediated protection 
appeared to reflect induction of NRF2-regulated anti-oxidant genes (19) and NRF2 is a known 
inhibitor of OC differentiation (32), we next investigated the effect of the SMAs on the 
induction of NRF2 response genes in day 5 OCs. This showed that both SMA 11a and 12b, 
but not 19o, increased mRNA for Heme oxygenase-1 (HMOX1), GCLC, and GCLM (Figure 
5F-H. This dramatic increase in anti-oxidant response gene mRNA was mirrored by a 
significant reduction in the level of ROS produced by OCs following exposure to SMA 11a or 
12b but not 19o (Figure 5I). As M-CSF and RANKL, individually and in combination, 
stimulate a ROS response that is required for the differentiation of mature OCs (11,12), this 
inverse increase in anti-oxidant response genes and decrease in OC ROS production following 
SMA treatment provides a potential mechanism for the ability of both SMA 11a and 12b to 
inhibit OC fusion and function despite the failure of SMA 11a to alter the levels of markers 
associated with driving osteoclastogenesis. The combination of decreased ROS and regulators 
of OC differentiation presumably explains the increased efficacy of SMA 12b (relative to 11a) 
in suppressing functional maturation of OCs, although 11a was more effective at preventing 
bone resorption. 
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4. Discussion 
 
It has been widely established that helminths are capable of skewing immune responses in 
order to improve their survival and prevent expulsion from the host and that this can impact on 
other infections as well as medical conditions associated with aberrant inflammatory responses 
(33). In the context of their potential protection against arthritis, helminths promote a strong 
Th2 immune response that is thought to counter the Th1/17 responses that dominate this 
disease (34). However, previously, our work has demonstrated that the helminth product ES-
62 disrupts the IL-17 network in arthritis models without promoting a Th2 phenotype: rather, 
by resetting homeostatic regulatory mechanisms (regulatory B cell and IL-22-dependent 
synovial fibroblast tissue repair responses), ES-62 acts to interfere with a number of the key 
pathological processes required to drive inflammation and disease (14,17,22,35). Thus, this 
single excretory-secretory product adopts a mechanism of action distinct from that commonly 
observed with live helminth infections, but that effectively redirects the immune system from 
its state of hyper-responsiveness.  
 
Herein, we now show that ES-62 also protects against the development of arthritis in the CIA 
model by modulating the progenitor populations that directly impact on bone remodeling in 
arthritic disease. Thus, consistent with its ability to reset homeostatic regulation, ES-62 
exhibited an ability to return the levels of HSC and OC BM progenitors found in arthritic 
animals towards those found in healthy, ÒNaveÓ animals and also to skew the 
RANK/OPG/RANKL axis such that OCPs would be less responsive to pathogenic signalling 
and result in less Cathepsin K
+
 OCs differentiating in the inflamed joint. Furthermore, in line 
with the finding that OCPs in the BM are increased in the SKG spontaneous model of arthritis 
(24), we witnessed an increase in the monocyte and OCP population in animals with CIA and 
treatment of these animals with ES-62 returned the numbers of monocytes, and potentially 
OCPs back to the levels found in healthy animals. At the same time, the expression of CD115 
Ð necessary for OC differentiation - on both of these progenitor populations was decreased 
following ES-62 treatment. Perhaps even more impressively, ES-62-treated CIA animals had 
an altered profile of functional OC maturation ex vivo compared to PBS-treated controls, 
suggesting that even limited exposure to ES-62 in vivo could have a lasting impact on the 
potential for pathogenic osteoclastogenesis in arthritis. With regard to how ES-62 modulates 
the progenitor populations in the BM, it is known that this worm product subverts TLR4 and 
MyD88 signaling to enact its immunomodulatory effects on cells (36). Interestingly, 
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expression of TLR4, and MyD88 is required for HSC differentiation to myeloid cells 
following LPS stimulation (37). Thus, MyD88 present in HSCs may serve as a potential target 
for ES-62 in resetting baseline levels of HSCs, and OCPs, with this molecule providing the 
first example of a defined helminth ES product rewiring bone remodeling progenitor 
populations in vivo to protect against the development of musculoskeletal disease. 
 
In addition to the effects of ES-62 in vivo, the worm product directly inhibits OC 
differentiation in vitro: this ability is reminiscent of previous studies showing that a distinct 
glycoprotein within crude ES from the human tapeworm Spirometra erinaceieuropaei was 
able to inhibit in vitro OC differentiation and reduce inflammatory cytokine production 
although the molecular mechanisms underlying these effects were not investigated (38). More 
recently, Chen et al. (2016) and Sarter et al. (2017) both demonstrated instances where live 
worm infections were capable of reducing inflammatory disease in murine arthritis models, 
thereby resulting in fewer OCs at the inflamed joint (34,39), with the latter group going on to 
demonstrate that Heligmosomoides polygyrus (H)ES was capable of inhibiting the 
differentiation of OCs in vitro, although again no mechanistic information was provided (39). 
Whilst, similar concentrations of ES-62 and HES (50 µg/ml) have been used to inhibit OC 
differentiation (39), in vitro,  HES contains the full complement of  excretory-secretory 
products from H. polygyrus (likely hundreds in number (40)) and it is possible that only one or 
two components may exert similar effects to ES-62. This suggests that the active ingredient(s) 
in HES may be more potent than ES-62. However, in contrast to HES-induced OC inhibition, 
where the parasite products were present throughout the culture, ES-62 and the SMAs 
exhibited an inhibitory effect on cells that had already been exposed to M-CSF and RANKL 
for four days. Thus, ES-62 and the SMAs were able to prevent the fusion and maturation of 
OCs even at a late stage of differentiation.  
 
The differential effects of ES-62 and the SMAs in vitro with respect to differentiation of OC 
from BM derived from Nave C57BL/6 mice may simply reflect the higher (~10 fold) molar 
concentrations of the SMAs relative to that of the active PC-moiety of the parent ES-62 
structure. Moreover, the SMAs contain a sulfonyl functional group in place of the phosphate 
group of the PC-containing molecules used in this study, which by providing additional 
stability may explain the relative potency of the SMAs (especially with respect to 
phosphorylcholine alone) in inhibiting OC differentiation and functional maturation. 
Nevertheless, as we have found in our previous CIA studies (16,17), ES-62 appears to exhibit 
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more potent effects under inflammatory conditions in vivo relative to its direct actions on 
ÒnormalÓ isolated cells in vitro and this seems to reflect that, rather than suppressing responses 
per se,  ES-62 acts to downregulate aberrant pathological signals to homeostatically restore 
steady-state responses. Alternatively, in vivo, ES-62 may target a cell network or induce 
systemic cellular or mediator effects that we have not yet recapitulated in vitro. Moreover, 
although we have generally found ES-62 to maximally modulate myeloid cell responses at 1-2 
µg/ml in vitro (e.g.18,19), we have previously shown the worm product to exhibit differential 
effects on nave and activated B cell responses in vitro when stimulated with low or high 
concentrations (41). Overall, this suggests that ES-62 effects particular responses in a 
concentration and cell-dependent manner. 
 
Our previous studies revealed that there are some differences in mechanism of action between 
the structurally similar SMA 11a and 12b despite both being modelled on the PC component 
of ES-62. Thus in CIA, SMA 11a preferentially targets IL-17 signaling (17), while SMA 12b 
predominantly targets NRF2, the NLRP3 inflammasome and IL-1β (19). Furthermore, 
microarray analysis on BM-derived macrophages stimulated with SMA 12b highlighted 
several pathways that were affected following SMA treatment and, of importance to this study, 
identified a number of osteoclastogenic targets. These included NFATc1 and c-Fos, which are 
both required for the differentiation of OCs (10,19,42) and reflecting this, in the current study, 
SMA 12b down-regulated mRNA levels of the main regulator of OC differentiation, NFATc1. 
The down regulation of NFATc1 mRNA levels likely resulted in the observed effects on the 
expression of mRNA for genes required for OC differentiation and function such as DC-
STAMP, Cathepsin K and MMP9. Perhaps surprisingly, SMA 11a, unlike SMA 12b, was 
unable to modulate OC-related mRNA transcription in this study. Our previous data on 
macrophages also indicated that exposure to SMA12b but not 11a for 4 h promoted NRF2 
signalling (19) but our further studies now suggest that 11a also induces anti-oxidant 
responses, albeit this is not seen until ~24 h (unpublished data).  Consistent with this, both 
SMAs were able to generate an anti-oxidant response in the present work as shown by 
increased HMOX-1, GCLC and GCLM gene expression by 24 h. NRF2 is also a negative 
regulator of osteoclastogenesis as nrf2
-/-  
BM produces higher numbers of OCs compared to 
WT BM as a result of increased ROS production (43), which is utilised by OCs to enhance 
differentiation following both M-CSF and RANKL stimulation (11,12). Both SMA 11a and 
12b increase expression of these anti-oxidant genes that are regulated by NRF-2 and inhibit 
ROS production resulting from M-CSF plus RANKL stimulation, suggesting that their ability 
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to generate a potent and robust anti-oxidant response prevents the differentiation of mature 
OCs. Although, we have not definitively shown that the SMAs utilise NRF2 to drive an anti-
oxidant response to inhibit OC differentiation, future studies exploiting nrf2-/- mouse models 
might provide valuable insight into the role the anti-oxidant response plays in SMA-mediated 
inhibition of OC differentiation and functional maturation (32,43).  
 
Interestingly, inhibition of osteoclastogenesis by ES-62 and the SMAs was achieved in BM 
from Nave animals from both arthritis-prone and more resistant strains of mice. CIA is 
reproducibly induced in DBA/1 mice with approximately 80-100% incidence while CIA 
incidence in C57BL/6 mice can range between 0 and 60% (28). Thus, in spite of the relative 
differences in disease susceptibility between these strains, ES-62 and the SMAs were able to 
inhibit not only the fusion of smaller TRAP+ OC precursors into large multinucleated OCs but 
also the bone-resorption activities of such OCs in both cases. This may suggest a therapeutic 
potential even in humans highly susceptible to developing disease. 
 
In summary, we show that exposure to the parasitic helminth product ES-62 reduces the pool 
of progenitors in the BM of CIA-animals and results in an altered course of monocyte/OC 
differentiation. Mechanistically, this is because ES-62, and SMAs based on the active PC 
moiety of ES-62, can inhibit the differentiation and fusion of OCs in vitro and the SMAs are 
capable of inducing NRF2-related anti-oxidant genes in OCs. Together these data are 
representative of a novel area of research linking the immunomodulatory capabilities of 
parasitic helminths and osteoimmunology that has perhaps previously been overlooked. 
Therapeutically, this could have ramifications for RA, as well as other OC-driven pathologies, 
as ES-62 not only prevents the inflammatory pathology of CIA but also rewires the effector 
cells to a ÔsafeÕ phenotype that could provide longer lasting benefits beyond current 
therapeutic interventions.  
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Figure Legends 
 
Fig. 1. ES-62 alters the progenitor populations in the BM of arthritic animals. Arthritic scores 
of DBA/1 mice undergoing CIA from challenge until cull at Day 29 (PBS-treated CIA animals, 
n = 8; ES-62-treated CIA animals, n = 6) (A) and the scores of all animals used in the study 
obtained from four independent CIA models at cull (PBS-treated [n = 30] and ES-62-treated 
[n = 20] CIA animals) (B). Joint sections of representative animals (PBS-CIA, score 7 and ES-
62-CIA, score 0) in each treatment group were subjected to histological analysis employing 
H&E staining (C - scale bar = 400 µm) and analysis of expression of Cathepsin K by 
immunofluorescence (D - DAPI Ð Blue; Cathepsin K Ð Red; scale bar = 500 µm). The number 
of Cathepsin K
+
 multinucleated cells within the joints of animals (Nave (n = 4), PBS (n = 3) 
and ES-62 (n = 4); three fields of vision (FOV) per sample) were enumerated (E). BM was 
taken from Nave (n = 8), PBS (n = 12) and ES-62 (n = 7) treated CIA animals to analyse the 
frequency of hematopoietic stem cells (HSCs - Lineage
neg
Sca-1
+
CD117
+
) (F). QIAzol lysates 
of bone-lining cells from the femur and tibia of animals was analysed for Osteopontin mRNA 
(Nave, n = 4; PBS, n = 8; ES-62, n = 7) (G). BM from CIA animals was analysed by flow 
cytometry for the phenotypic markers of monocytes and OC precursors following gating of 
single CD3
-
 B220
-
Ter119
- 
cells.  The gating strategy for differentiation of monocytes from 
neutrophils is demonstrated (Ly6C
high
Ly6G
-
 population) and this is subsequently used to 
identify the OC precursors (CD11b
low
Ly6C
high
Ly6G
-
 population) that reside within the global 
monocyte population (H). The percentage of monocytes and osteoclast precursors (I and J) 
from Nave (n = 24), PBS-treated (n = 26 for I and 30 for J) and ES-62-treated (n = 19) CIA 
animals as well as the expression of CD115 on the surface of monocytes and osteoclast 
precursors (K and L; Nave, n = 4; PBS, n = 8; ES-62, n = 7) was examined. Data are pooled 
from four independent experiments and are presented as mean values of individual mice ± 
SEM. Two-tailed Mann-Whitney t test or Kruskal-Wallis with DunnÕs multiple comparisons 
was used for non-parametric data and one-way ANOVA with Fishers LSD was used to 
analyze parametric data where * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
Fig. 2. Exposure to ES-62 in vivo alters the ex vivo responses of osteoclast progenitors and 
decreases RANK and RANKL mRNA in the BM of arthritic animals. Non-adherent BM, 
Nave (n = 3), PBS-treated CIA (n = 3) and ES-62-treated CIA (n = 3) from DBA/1 mice, was 
harvested at cull and cultured for 4-6 days with 30 ng/ml M-CSF and 50 ng/ml RANKL. 
Medium was refreshed on day 4 and osteoclast differentiation was assessed by TRAP staining. 
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The number (A) and size (B) of live TRAP
+
 multinucleated osteoclasts with >3 nuclei were 
calculated using Image J analysis software. Representative images of osteoclasts (PBS-CIA, 
score 10 and ES-62-CIA, score 0) at each time point are provided with red arrows indicating 
dead osteoclasts (C - scale bar = 1000 µm). Data are from one experiment performed in 
triplicate presented as mean ± SD and are representative of two experiments, although the 
kinetic profile of osteoclast differentiation was observed with BM from three mouse models 
comparing naive and PBS-CIA mice. Representative images of dentine slices following 14-
day culture with OCs from Nave (n = 3), PBS (mean score 6; n = 4) or ES-62 (mean score 3; 
n = 4) treated CIA-animal BM (D - scale bar = 400 µm). Image J software was used to 
calculate the % of resorption and data are presented as mean ± SEM of individual mice 
performed in triplicate (E). mRNA transcripts from Nave (n = 4), PBS-treated CIA (n = 8) 
and ES-62-treated CIA (n = 7) animals, collected at cull, were analysed for (F) RANK 
(tnfrsf11a), (G) OPG (tnfrsf11b) and (H) RANKL (tnfsf11). Data from a single experiment are 
shown as mean values (of triplicate analyses) ± SEM of individual mice and are representative 
of four experiments. Two-way ANOVA with LSD FisherÕs test was used to analyse 
experimental conditions comparing PBS-treated CIA with Nave and ES-62-treated CIA 
animals, where *** = p < 0.001. Kruskal-Wallis with DunnÕs post-test was used to analyse 
non-parametric data where * = p < 0.05 and ** = p < 0.01.   
 
Fig. 3. ES-62, and phosphorylcholine inhibit the fusion of osteoclasts in vitro. Non-adherent 
BM, from healthy Nave C57BL/6 and DBA/1 mice was harvested and cultured for 4 days 
with 30 ng/ml M-CSF and 50 ng/ml RANKL, at which point, medium was removed and cells 
were incubated in fresh medium or medium containing 50 µg/ml of ES-62, PC, PC conjugated 
to BSA (PC-BSA) or BSA. Osteoclast differentiation at day 5 was assessed by TRAP staining 
and Image J was employed to measure the number and size of multinucleated osteoclasts with 
>3 nuclei present (A-D).  Representative images of experimental conditions are provided (E - 
scale bar = 1000 µm). To assess the ability of ES-62 to inhibit osteoclast bone resorption, 
nave C57BL/6 non-adherent BM was cultured on dentine slices with BSA, ES-62, PC-BSA 
or PC treatment commencing from day 4 until day 14 when resorption was assessed and 
representative images are provided (F and G - scale bar = 400 µm). The effect following 24-
hour pre-treatment of ES-62, BSA, PC-BSA or PC on cell viability was assessed using 
7AAD
+
CD11b
+
 cells by flow cytometry (H). Data are pooled from four (A Ð D; ES-62 
treatment was only performed in two of these experiments); two (G: ES-62 treatment reduced 
the capacity of the cells to resorb bone in both experiments but this inhibition was only 
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significant compared to the control cells in one experiment) or three (H) independent 
experiments performed in triplicate and presented as mean ± SEM. Data were analysed using 
one-way ANOVA with FisherÕs LSD post-test to compare experimental conditions to M+R 
where * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.  
 
Fig. 4. Small molecule analogues (SMAs) of ES-62 inhibit the differentiation and function of 
osteoclasts. Non-adherent BM from Nave C57BL/6 and DBA/1 mice was harvested and 
cultured for 4 days with 30 ng/ml M-CSF and 50 ng/ml RANKL, at which point medium was 
refreshed and cells were incubated in medium or medium containing 5 µg/ml SMA 11a, 12b 
or 19o. Osteoclast differentiation was assessed at day 5 by TRAP staining and Image J was 
employed to measure the number and size of osteoclasts present (A - D). Representative 
images of TRAP-stained SMA-treated osteoclasts are provided (E - scale bar = 1000 µm). The 
functional capacity of SMA-treated C57BL/6 osteoclasts was assessed on dentine slices after 
14 days where SMAs were added when medium was refreshed from day 4 onwards and 
representative images of resorption pits provided (F and G - scale bar = 400 µm). Osteoclast 
precursor cell death following 24-hour treatment with SMAs using 7AAD staining was 
measured (H). Data are from three experiments performed in triplicate and presented as mean 
± SD. One-way ANOVA with FisherÕs LSD post-test was used to analyse experimental 
conditions compared to M+R, where * = p < 0.05 ** = p < 0.01 and *** = p < 0.001. In G, 
19o is not significantly different to M+R but is significantly different to 11a (p<0.001) and 
12b (p<0.05). 
 
Fig. 5. SMA 12b down-regulates osteoclast-specific gene transcription and induces an anti-
oxidant response during OC differentiation in vitro. Non-adherent BM, from C57BL/6 mice, 
was harvested and cultured for 4 days with 30 ng/ml M-CSF and 50 ng/ml RANKL (M+R), at 
which point medium was refreshed and cells were incubated in medium or medium containing 
5 µg/ml of SMAs 11a, 12b or 19o. At Day 5 of culture, osteoclasts were lysed, mRNA 
extracted and cDNA synthesized. Expression of nfatc1 (A), mmp9 (B), ctsk (C), dc-stamp (D), 
itgb3 (E), hmox-1 (F), gclc (G) and gclm (H) mRNA was determined by qRT-PCR to assess 
the phenotypic profile of osteoclasts. Likewise, on day 5 of culture, following the 24-hour 
treatment with SMAs, osteoclasts (I) were stained using the fluorescent stain DCF-DA to 
measure the presence of ROS. Data are collated from three experiments performed in triplicate, 
normalised to the M+R control and presented as mean ± SD. One-way ANOVA with DunnÕs 
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post-test was used to analyse experimental conditions compared to M+R, where * = p < 0.05, 
** = p < 0.01 and *** = p < 0.001.  
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